COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration

Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.

DOT Issues Safety Advisory Notice for the Transportation of COVID-19 Diagnostic Samples

Covid-19 rapid response
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest
Share on whatsapp
WhatsApp
Share on email
Email
Share on facebook
Share on twitter
Share on linkedin
Share on google
Share on whatsapp
Share on email

Shipping guidelines for SARS-CoV-2 specimens were emphasized as many clinical laboratories are not shipping specimens correctly.

The US Department of Transportation (DOT) issued a Safety Advisory Notice for the transportation of COVID-19 diagnostic samples. According to the Centers for Disease Control and Prevention (CDC) Division of Laboratory Systems (DLS) notice to clinical laboratory professionals, “This notice was published in response to inspections that revealed COVID-19 diagnostic test samples that were improperly marked or packaged for shipping.”

The CDC DLS announcement was released on July 1, 2020, however, the Safety Advisory Notice was initially issued by the DOT on June 19, 2020. 

“Investigators from [the DOT’s Pipeline and Hazardous Materials Safety Administration’s] PHMSA’s Office of Hazardous Materials Safety (OHMS) recently conducted compliance inspections and found several instances of improperly marked or packaged diagnostic samples that were offered for transportation, which included sample vials packaged without rigid outer packagings,” the DOT said in their Safety Advisory Notice. “In response, PHMSA has developed this Safety Advisory Notice to provide information on the [Hazardous Materials Regulations] HMR related to offering and transporting these materials.”

In the Safety Advisory Notice, the DOT provided specific instructions for many of the considerations for packaging, including:

  • triple packaging,
  • package capability requirements,
  • transport by air,
  • required markings,
  • overpack markings,
  • emergency response information, and
  • closure instructions.

Clinical laboratories that are shipping SARS-CoV-2 diagnostic specimens can review the detailed instructions in the Safety Advisory Notice here.

Related Resources:

CDC Alert: DOT Issues Safety Notice for Transportation of COVID-19 Diagnostic Samples

Safety Advisory Notice for the Transportation of COVID-19 Diagnostic Samples

COVID-19 TESTING DATA

Helping Your Lab Stay Afloat During Challenging Times

Dear Colleague,

Robert L. MichelIn these challenging times for our colleagues in clinical laboratories, pathology practices and hospital administration, The Dark Intelligence Group (TDIG) — through generous grants from our partners — is bringing you the COVID-19 STAT Intelligence Briefings.

We’ve added analysts, writers and skilled editors to the COVID-19 STAT team to uncover, analyze, and immediately report to you what’s happening with the SARS-CoV-2 pandemic, packaged with the insights you need to deliver quality testing for patient care and keep your lab’s financial ship afloat. As part of our mission, we are also bringing you real-time data from our partners around testing that you will not find anywhere else.

Please let me know how we can better improve this service to fit your needs. If you would like to offer a grant to keep our mission going with this site, please contact me at rmichel@darkreport.com.

Sincerely,

Robert L. Michel
President, Founder
The Dark Intelligence Group